In these investigations the therapeutic efficacy of PKC412 was restricted to MLL-rearranged leukemia cells carrying either FLT3 amplifications or FLT3 activating mutations; whereas no therapeutic benefit could be observed in cells in which FLT3 was unaltered [7], [18]. The gene discussed is KMT2A; the disease is leukemia.